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Abstract—Fibronectin (Fn) is an essential extracellular
matrix (ECM) glycoprotein involved in both physiological
and pathological processes. The structure–function relation-
ship of Fn has been and is still being studied, as changes in its
molecular structure are integral in regulating (or dysregulat-
ing) its biological activities via its cell, matrix component,
and growth factor binding sites. Fn comprises three types of
repeating modules; among them, FnIII modules are mechan-
ically unstable domains that may be extended/unfolded upon
cell traction and either uncover cryptic binding sites or
disrupt otherwise exposed binding sites. Cells assemble Fn
into a ﬁbrillar network; its conformational ﬂexibility impli-
cates Fn as a critical mechanoregulator of the ECM. Fn has
been shown to contribute to altered stroma remodeling
during tumorigenesis. This review will discuss (i) the signif-
icance of the structure–function relationship of Fn at both
the molecular and the matrix scales, (ii) the role of Fn
mechanobiology in the regulation of tumorigenesis, and (iii)
Fn-related advances in cancer therapy development.
Keywords—Fibronectin conformational ﬂexibility, Fibronectin
mechanics, Tumor stroma, Tumor progression.
Fn AND ITS SIGNIFICANCE IN CANCER
Fibronectin (Fn) is one of the most abundant
extracellular matrix proteins (ECM) along with colla-
gen. Fn was ﬁrst discovered as a high molecular weight
ﬁbroblast cell surface protein in the early 1970s,64,126
and then as an extracellular ﬁbrillar network sur-
rounding ﬁbroblasts through immunoﬂuorescence and
scanning electron microscopy.155 Early isolation of Fn
revealed a dimeric glycoprotein with two subunits
measuring ~220 kDa165 held together by disulﬁde
bonds.66 Most Fn is synthesized by hepatocytes to
circulate in the bloodstream as soluble plasma Fn.
Various cells also secrete Fn, named cellular Fn, to be
directly assembled into an insoluble ﬁbrillar network.
Plasma and cellular Fn mediate different biological
behaviors; plasma Fn is essential in clots during early
wound healing, whereas cellular Fn mediates late
wound healing, neovascularization, and angiogenesis
(Fig. 1a).50,147 Fn is also implicated in other physio-
logical (e.g., embryogenesis156) and pathological30
(e.g., ﬁbrosis, cancer) processes.
Originally, Fn was discovered because ﬁbroblast
cells lack a cell surface protein after viral transforma-
tion.64,155 However, the loss of Fn is not a good mar-
ker of malignancy, as some anchorage-independent
tumorigenic cell lines are still able to assemble a ﬁb-
rillar Fn network.73 Further studies assessing the role
of Fn in malignancy reveal high concentrations of
plasma Fn after mice were inoculated with Ehrlich
tumor cells,167 but plasma Fn ﬂuctuates with clinical
events such as chemotherapy.24,168 Other reports ad-
dressed the controversial deposition of Fn in tumors
and found that it is absent in tumors but abundant in
the surrounding stroma.8,144 As such, understanding
Fn dynamics, i.e., Fn deposition and remodeling dur-
ing tumorigenesis, is essential to expanding our
knowledge of cancer.
The tumor stroma is a complex microenvironment
in which components are recruited or remodeled to
facilitate invasive growth and metastasis.43,54 There-
fore, speciﬁc focus is placed on understanding how the
surrounding ECM is altered to mediate tumor pro-
gression.75,130 Cancer-associated ﬁbroblasts (CAFs)
are major sources of increased ECM deposition and
altered remodeling97 to create tracks for cancer cell
invasion.46 This review will discuss (i) the importance
of Fn structure, matrix assembly, and mechanics in
invasive tumor growth, and (ii) their relevance to im-
prove therapeutic strategies and diagnostic tools.
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Fn MECHANOREGULATION OF VARIOUS
CELLULAR ACTIVITIES
Fn is a mechanoregulator of the ECM due to its
conformational ﬂexibility14,35,38,159 in both plasma1
and ﬁbrillar forms.2,139 Fn consists of 3 repeating
modules: FnI, FnII, and FnIII.30,124 FnI and FnII are
mechanically stable modules as they are stabilized by
disulﬁde bonds, but FnIII lack these disulﬁde bonds
and are sensitive to external mechanical forces.67 FnIII
modules are made up of 7 b strands within 2 anti-
parallel b sheets surrounding a hydrophobic core, with
FnIII10 holding a RGD loop (cell-binding site)
between the F (6th) and G (7th) b strands.96 The RGD
sequence is a ubiquitous cell binding region as it has
also been found in other proteins such as ﬁbrinogen,
vitronectin, laminin, and thrombospondin.125 Fn con-
tains two sites that collaboratively confer adhesion,112
the RGD site on FnIII10 and the PHSRN synergy site
located on the adjacent FnIII9.
6 Simultaneous
engagement to both RGD and PHSRN sites is essen-
tial for integrins a5b1
111 resulting in a binding that is
highly sensitive to Fn molecular conformation.85 In
contrast, the binding of most other integrins, including
avb3 integrins, requires engagement only to the RGD
loop and is not (or less) sensitive to Fn conforma-
tion.79 Brieﬂy, the RGD loop is separated from the
PHSRN site by 30–40 A˚ and a small rotation between
FnIII9 and FnIII10 orients the two cell binding sites on
the same side of the Fn molecule.88 Therefore, any
change either in the orientation (i.e., in the relative
angles between the two adjacent modules) or in the
spacing between adjacent modules (e.g., as it occurs
during FnIII10 unfolding and shown in Fig. 1b), alters
the type of transmembrane receptors used by cells to
bind to the Fn matrix,106 and the subsequent down-
stream signaling. Another important region on Fn
essential to mechanoregulation is the FnIII12–14 se-
quence, which binds various growth factors98 for sus-
tained, localized signaling. Immobilization of growth
factors modulates different downstream signaling.3
Speciﬁcally, Fn-bound vascular endothelial growth
factor (VEGF) mediates structured vascularization
whereas soluble VEGF directs large, leaky vascula-
ture.90 Thus, Fn conformational ﬂexibility is able to
regulate cell activity via integrin speciﬁcity and growth
factor binding.
Various cells are able to incorporate plasma Fn into
the predominantly cellular Fn based-ECM of any tis-
sue32,114 Additionally, ﬁbroblasts are able to deposit a
Fn matrix by secreting and assembling Fn into ﬁbers at




133 binding to Fn were shown to participate in
Fn matrix assembly. Assembly requires mechanical
stimulation provided by cellular traction forces to
induce a conformational change in Fn and expose
cryptic binding sites that mediate Fn polymeriza-
tion.18,92 Recent advances in super-resolution micro-
scopy such as direct stochastic optical reconstruction
microscopy provide insight to the ordered structure of
Fn within bundled ﬁbers, demonstrating that Fn mo-
lecules are aligned within ﬁbers with alternating N-
terminal and C-terminal overlapping regions.45 Fn
maturation follows deposition and involves the poly-
merization of nascent deoxycholate-soluble Fn (12–
20 nm in diameter)22 ultrathin ﬁbrils into mature
deoxycholate-insoluble Fn thick ﬁbrils networks (up to
200 nm in diameter).45,102 Although multiple Fn con-
formations coexist in the matrix (and in individual
ﬁbrils), the average Fn conformation has been reported
to evolve during ECM maturation from compact/ex-
tended Fn in early ﬁbrils to extended/unfolded Fn in
mature ﬁbrils and matrices.11,87,139 The polymerization
of Fn in extended conformations47 stimulates cell
growth,142 a process that may be mediated by inter-
actions with heparin sulfate proteoglycans (another
matrix component to which Fn binds).62,141 Fn net-
works may also be initiated via self-assembly. Fn
contains conformational-dependent59 binding sites for
itself located on FnI1–5, FnIII1–2, FnIII4–5, and
FnIII12–14.
45 These Fn–Fn interactions may be medi-
ated by interactions with FnIII10.
57 Furthermore,
fragments of these binding sites have been shown to
inhibit Fn–Fn interactions and Fn ﬁbrillogenesis.103,108
Thus, changes to initial Fn conformations are also
crucial in the regulation of Fn binding to other ECM
components (including itself), and modulate further
ECM deposition and remodeling.
The assembly of an initial Fn network138 is often a
prerequisite for the downstream deposition of colla-
gen.101,140,148 Reciprocally, the co-deposition of colla-
gen has several effects on the initial Fn matrix: it assists
further Fn remodeling by matrix metalloproteinases
such as MT1-MMP,135 it stabilizes the ECM,140 it
promotes cell proliferation and maintenance of
microtissue morphology (ECM reorganization),134 and
it facilitates cell migration.143 The reported co-local-
ization of both Fn and procollagen within the cell
further demonstrates a likely synergistic relationship
between these two ECM proteins.89 Fn contains a large
(multimodular) collagen binding site51 located on
modules FnI6FnII1–2FnI7–9.
68 Fn regions within this
site119 collectively bind76 to the collagen a1(I) chain
between residues 757 and 791.33,81 Collagen binding
stabilizes the 90 kink between FnI6FnII1–2FnI7 and
FnI8–9,
36 which is believed to assist Fn in maintaining a
compact/relaxed conformation in the stroma, further
regulating normal tissue homeostasis.
Fn-coated beads restrained by optical traps reveal
cells’ ability to sense their environment and to respond
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to increased external resistance25 due to the strength-
ening of cytoskeletal tension, as later conﬁrmed by
traction force microcopy.154 Additionally, lysophos-
phatidic acid (from platelets) mediates Rho-activated
stress ﬁber formation and enhances Fn matrix assem-
bly, revealing the importance of cellular tension in Fn
ﬁbrillogenesis.12,169,171 Brieﬂy, a5b1 integrins translo-
cating along actin cytoskeletal bundles elongate Fn
molecules117 with varying amounts of force,113 which
initiates Fn polymerization and induces cytoskeletal
tension.58 L8, an antibody known to bind Fn within
FnI9 and FnIII1 and to inhibit Fn ﬁber assembly when
added to ﬁbroblast culture medium,23 increases its
binding to Fn when Fn monolayers deposited on
rubber substrates (cell-free system) were mechanically
strained to expose a cryptic binding site.173 These
studies suggest that isolated Fn must unfold to bind to
itself and begin the ﬁbrillogenesis process. Detailed
analysis of Fn matrix assembly and maturation indi-
cates that Fn ﬁbers are highly elastic65,82,115 and
heterogeneous as they comprise multiple molecular
conformations, from compact/relaxed to extended/
unfolded.87,139 The elasticity of Fn ﬁbers can be at-
tributed to the conformational ﬂexibility of FnIII
modules (lacking disulﬁde bonds) that are allowed to
extend/unfold upon cellular traction, as suggested by
FIGURE 1. Structure-function relationship of fibronectin in healthy and pathological environments. In healthy environments, the
ECM is in balance between relaxed and strained conformations to maintain normal tissue homeostasis. However, the ECM in
tumor stroma has lost its integrity and starts mediating an altered ECM phenotype. The relaxed ECM (a) contains mostly compact/
extended fibronectin, whereas in the strained ECM (b), fibronectin undergoes conformational changes to resist cell-mediated
traction forces. These changes to fibronectin lead to exposure of soluble factor (i.e., VEGF) binding and cryptic sites. Furthermore,
these conformational changes facilitate specific matrix component binding to mediate ECM remodeling or modify integrins
engagement and activation (i.e., avb3 vs. a5b1) to consequently modulate cell behaviors. Moreover, unfolded Fn is correlated with
enhanced fiber strain and bulk ECM stiffening. Therefore, tumor-associated fibronectin assembled in tumor stroma facilitates a
cascade of dysregulated downstream signaling for tumor progression.
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steered molecular dynamics simulations86 and ﬂuores-
cence resonance energy transfer.139 Importantly, an
in vivo study also portrays the critical role of Fn con-
formational changes in modulating tissue function
(e.g., the exposure of FnIII1 mediated by skeletal
muscle contraction leads to vasodilation).60 Collec-
tively, Fn’s cell-induced changes in conformation
implicate this glycoprotein as a critical mechan-
otransducer in translating mechanical signals from the
external environment into biochemical signals medi-
ated by integrin clustering and cytoskeletal ten-
sion.26,150
ROLES OF CONFORMATION ANDMECHANICS
OF Fn IN TUMORIGENESIS
In fetal tissues and cancers, cellular Fn is larger100
and alternatively spliced132 to contain the following
sequences: IIICS, ED-A, ED-B, which confer addi-
tional conformational changes to Fn.10,16,39,149 Fn ED-A
is found at sites of tissue remodeling and during dys-
regulated signaling, it promotes a ﬁbrotic phenotype136
for tumorigenesis77 and for neovascularization of
metastases.127 This splice variant enhances VEGF-C
secretion via the PI3 K/Akt signaling pathway.163 Fn
ED-A secreted by endothelial cells (isolated from
tumors) also induces epithelial-mesenchymal transition
of cancer cells by activating the FAK-Src signaling
pathway via a9b1.
116,137 Instead, Fn ED-B is found in
the tumor stroma72 and in the tumor vasculature.19
This splice variant of Fn has been found to enhance
cell adhesion and formation of focal adhesions for cell
spreading.56 ECM stiffening, a hallmark of cancer, has
been found to enhance ED-B splicing of Fn to prop-
agate a tumorigenic phenotype.13 Thus, changes in
conformation, mechanics, and alternative splicing of
Fn synergistically regulate tumorigenesis.
Fn is up-regulated in the tumor stroma.30 Its en-
hanced synthesis110 is attributed to CAFs, ﬁbroblasts
with altered phenotype and function.74 CAFs are
activated by TGF-b83 or transformed by Fn-tissue
transglutaminase complexes contained in microvesicles
released from cancer cells.5 Breast tumor CAFs deposit
an initially dense, unfolded20 and stiff153 Fn matrix
that facilitates an ‘integrin switch’, i.e., a change from
primarily a5b1 binding (that depends on Fn confor-
mation) to that of mostly avb3 binding (that is inde-
pendent of Fn conformation),34,151 resulting in
enhanced pro-angiogenic (VEGF) secretion.152,153
Changes to the material properties of Fn can in turn
mediate a cascade of signaling events for tumorigenesis
(e.g., ECM unfolding, stiffening, tumor angiogenesis,
and tumor invasion) (Fig. 1b).
Under conditions of normal tissue homeostasis, Fn
mediates strong cellular adhesion. Upon matrix mat-
uration during healthy ECM remodeling (e.g., wound
healing, vascularization, embryogenesis) (Fig. 1a), Fn
gradually unfolds while cells become more contractile
and develop strong ﬁbrillar adhesions containing b1
integrins.4 a5b1 integrins binding to Fn stimulates
myosin II44 and RhoA-GTPase to form robust
peripheral ﬁbrillar adhesions.29 These strong adhesive
forces between Fn and a5b1 integrins (~93 pN)94 re-
duce migration of invasive cells.69 Fn conformational
changes are often responsible for an ‘integrin switch’ as
Fn conformation alters the type of integrins cells may
utilize to bind to the surrounding ECM. As detailed in
Section II, the most abundant Fn integrins, a5b1, re-
quire both the synergy and the RGD sites located on
FnIII9 and FnIII10, respectively, to form complexes
with Fn, which implies that strong a5b1-Fn binding is
conformation-dependent and occurs only when Fn is
in a nearly compact conformation. In contrast, avb3
integrins require only the RGD site, i.e., weaker avb3-
Fn binding is conformation-independent and occurs
even when Fn is unfolded during ECM remodeling.28
Weak Fn-avb3 adhesions
131 by cancer cells then lead to
greater cytoskeletal reorganization for enhanced
migration capacity9 and resistance against anoikis
(Fig. 1b).170 Once Fn conformation is altered during
tumorigenesis, cell–matrix interactions are dysregu-
lated and changes to downstream signaling take place.
As Fn contains binding sites for cells, growth fac-
tors, and matrix components, variations in Fn con-
formation during tumorigenesis alter multiple
microenvironmental interactions. The up-regulation of
Fn combined with the preferred utilization of avb3 in
the tumor stroma mediates the release and activation
of matrix metalloproteinase-2 (MMP-2), which favors
tumor invasion and metastasis.71,128 The resulting
remodeled Fn, likely degraded by MMP-2, may in turn
bind with altered afﬁnity37 to collagen ECM, which
may lead to the formation of dysregulated, crosslinked,
and stiff Col I93 tracks for enhanced invasion by cancer
cells.27,122 Although the deposition of collagen usually
requires the presence of provisional Fn, enhanced
secretion of TGF-b does lead to collagen ﬁbrillogenesis
and ﬁbrotic ECM remodeling even in the absence of
Fn.107
Besides conformation, stiﬀness of the ECM also
plays a role in tumorigenesis.55,93,120 ECM stiffening
not only promotes Fn ED-B splicing and Fn unfolding
for a pro-angiogenic integrin switch, but also con-
tributes to TGF-b activity,99 a phenomenon that can
inﬂuence myoﬁbroblast differentiation7,160 or epithelial
to mesenchymal transition (EMT) for tumor progres-
sion.91 Invasive cells preferentially migrate towards
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stiffer ECM (durotaxis).95,121 Durotaxis is mediated by
both the recruitment of avb3 integrins that re-organize
and reinforce the cytoskeleton9,123 at the leading edge
of cells70 and the extensions of ﬁlopodia.161 This
rigidity response is attributed to activation of p130Cas
via Fyn recruitment by receptor-like protein tyrosine
phosphatase alpha (RPTPa) at the leading edge of
these cells.84 As altered Fn is stiffer, it may direct
cancer cell invasion into the surrounding stroma for
eventual metastasis.
Finally, Fn binding to cell surfaces via integrins also
mediates clustering of growth factor receptors.164 En-
hanced levels of VEGF41 are secreted by breast cancer
cells (and/or ﬁbroblasts subjected to paracrine signal-
ing by breast cancer cells53 ) for tumor angiogene-
sis.31,48 An isoform of VEGF, VEGF165, increases
breast cancer and endothelial cell migration in pres-
ence of Fn (and heparin).104 Speciﬁcally, Fn forms a
complex with VEGF-receptor-2 and a5b1
78 to bind
VEGF157 on the heparin II binding domain located on
FnIII13–14.
158 Furthermore, ECM components such as
heparin or heparan sulfate facilitate an extended con-
formation of Fn to enhance VEGF binding105 in a pH-
dependent manner.49 As acidic environments promote
tumorigenesis,118 low pH in the tumor stroma may
contribute to these changes in Fn conformation and
subsequent tumor angiogenesis. Overall, the Fn matrix
is not only a mechanotransducing network but also a
chemical reservoir of signaling molecules for cells, as
Fn-bound VEGF facilitates organized vascular
sprouting and branching90 via enhanced activation of
MAPK through b1 mediated clustering of VEGFR2.
21
DEVELOPMENT OF Fn-BASED CANCER
THERAPY
During tumorigenesis, primary structure, confor-
mation, and mechanics of Fn are altered, which clearly
aﬀects its multiple biological functions. As the ECM
stiﬀens, alternative splicing of Fn increases,13 which
leads to additional conformational changes (in an al-
ready highly strained and stiff tumor-associated
matrix153) and promotes dysregulated downstream
cell–matrix interactions for tumor progression. Tar-
geting this altered Fn during tumorigenesis is therefore
extremely desirable. Using phage antibody technology,
molecular probes were successfully developed to dis-
tinguish between different unfolded (strained) states of
Fn.15 Additionally, CGS-1 and CGS-2 human anti-
body fragments were isolated and found to directly
target Fn containing ED-B in human tissues as well as
in other species.17 Another antibody fragment speciﬁc
for ED-B, scFv(L19), was fused to domains of inter-
leukin-12 to enhance cellular immunity, which led to
slower tumor growth and reduced metastasis52 while
injection of a radioactive-homodimer form of the fu-
sion protein,123 I-L19(scFv)2, in cancer patients
demonstrated the potential to image primary and me-
tastatic tumors noninvasively.129 Using E. coli
expressing bacterial thioredoxin, therapeutic vaccines
speciﬁc against ED-A and ED-B were also developed
and found to stimulate anti-ED-A and anti-ED-B
antibodies to reduce tumor growth.40,63 Biologically
active fragments of Fn were also utilized, particularly
for structure–function experiments portraying the
ability of Fn to bind to itself and regulate its own
function.61,103 Among them, a fragment derived from
the ﬁrst type III repeat in Fn, FnIII1C (named
anastellin),109 was reported to inhibit tumor growth,
angiogenesis, and metastasis.166 In vitro experiments
studying the mechanisms behind anastellin’s effects
revealed that anastellin bound Fn and induced a con-
formational loss of a Fn epitope containing ED-A,
which then activated MAPK and ﬁlopodia to stimulate
Fn remodeling.80 However, anastellin was also shown
to mediate an inﬂammatory and pro-angiogenic phe-
notype of stromal cells within tumors.172 Finally,
Fn-derived N-terminal and C-terminal heparin-bind-
ing domains, respectively named heparin I and heparin
II domains, were also found to inhibit cancer cell
adhesion and invasion by reducing avb3 expression and
MMP-9 activity.146 As advances are made in our
knowledge of Fn nanostructure (e.g., splice variants),
assembly (e.g., ﬁbrillogenesis, molecular arrangement
in ﬁbers, strain-induced conformational changes,
remodeling), and mechanics (e.g., contributions of
both elastic and viscoelastic properties of Fn to direct
cell behavior) during tumorigenesis, the development
of therapeutic strategies and diagnostic tools will
continue to improve to mitigate tumorigenesis.
CONCLUSIONS AND FUTURE PERSPECTIVES
Fn is able to trigger a wide range of cellular activi-
ties and is extremely dynamic, constantly undergoing
remodeling processes where one or more of its essential
properties are modiﬁed. Modulation of Fn dynamics is
likely a strategy for tumor stromal cells to respond to
microenvironmental changes (in particular, paracrine
signaling from cancer cells) and contributes actively to
tumorigenesis. However, because of the reciprocal
nature of cell–Fn interactions, it is still unclear whether
early Fn alterations in the tumor microenvironment
are a cause or a consequence of the disease.
Numerous Fn-linked tumorigenesis mechanisms
still need to be unraveled. As both plasma and cellular
Fn play an inextricable role in mediating diﬀerent
biological functions, delineating their respective con-
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tributions during tumorigenesis must be addressed.
Neither the mechanisms responsible for Fn assembly
into ﬁbers nor the detailed molecular structure of ﬁbers
are well understood, which would certainly help in
deﬁning the full range of parameters that regulate the
Fn structure–function relationship. Although it is now
well accepted that Fn assembly is dysregulated during
tumorigenesis and leads to altered materials properties
of the entire Fn network, it is likely that other
microenvironmental disorders, such as altered MMP
activity, additionally drive changes in Fn remodeling
to predispose the altered ECM for tumor progression.
Hence, understanding the means by which early Fn
alterations occur during tumorigenesis may pave the
way for the development of both diagnostic tools to
halt cancer growth at early stages and therapeutics to
prevent invasive cancer growth.
Tumor-associated Fn mechanobiology research is
critical to deconvolute the diverse materials properties
of the dysregulated tumor Fn, i.e., to distinguish
among physical (matrix topology, molecular confor-
mation), biochemical (binding aﬃnity, sequestration),
and biomechanical (elasticity, viscoelasticity) alter-
ations during disease progression. For example, aging-
and/or disease-induced Fn conformational changes
occurring at the molecular scale (e.g., unfolding) dic-
tate the binding of speciﬁc types of growth factors,
integrins, and matrix components, which has deep
implications in driving tumorigenesis. However, these
molecular conformational changes are usually accom-
panied by concurrent topological and mechanical
changes at a larger scale, which makes it diﬃcult to
unravel speciﬁc mechanisms and their chronology. As
such, the recent advances made towards understanding
the structure–function relationship of Fn in
tumorigenesis highlight the importance of utilizing
interdisciplinary approaches in cancer research.
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